Form 4: Day One Biopharmaceuticals Executive Sells 10,000 Shares Under 10b5-1 Plan

Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 10,000 shares of common stock at an average price of $16.0163 per share on April 18, 2024, under a pre-arranged trading plan.

Summary

• On April 18, 2024, Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 10,000 shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on October 10, 2023.
• The shares were sold at a weighted average price of $16.0163, with individual transactions ranging from $16.00 to $16.12 per share.
• Following the transaction, Blackman directly owns 1,174,662 shares of Day One Biopharmaceuticals.
• Blackman also indirectly owns 1,000,000 shares through the 2021 Blackman Family LLC, but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports an insider sale under a pre-arranged trading plan, which is a common and legal practice. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Insider sales are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares without being accused of trading on material non-public information. The market will likely interpret this sale in the context of the company's recent performance and future prospects.

Stakeholder Impact

• The sale could have a minor negative impact on shareholder sentiment, although it is likely to be minimal given the pre-planned nature of the transaction.

Key Dates